ClinicalTrials.gg
RecruitingNCT07200180Updated Jun 18, 2026

Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery

A Phase 3 interventional study of Аrgon-oxygen breathing mixture and Nitrogen-oxygen breathing mixture in Carotid Artery Disease and Carotid Artery Stenoses, sponsored by Negovsky Reanimatology Research Institute. Recruiting at 2 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Primary conditionCarotid StenosisRegistry: Carotid Artery DiseasesReclassifiedWhy we changed it
Registry
Carotid Artery Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carotid Stenosis
Why
  1. The study's listed conditions name Carotid Stenosis, a narrower term within Carotid Artery Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Negovsky Reanimatology Research Institute · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Currently, over 400,000 reconstructive surgeries on carotid arteries are performed annually worldwide, including carotid endarterectomy (CEA) and carotid stenting. These interventions have proven effective in preventing ischemic stroke in patients with hemodynamically significant carotid artery stenoses. However, even following a technically successful procedure, the risk of perioperative ischemic brain injury persists. According to meta-analyses, one in five patients exhibits covert ("silent") strokes after reconstructive interventions, with their frequency being ten times higher than that of clinically manifest events. Such lesions are associated with cognitive decline and an increased risk of dementia. An additional risk factor is the "no-reflow" phenomenon-an impairment of microcirculatory reperfusion that occurs even after the restoration of macrovascular blood flow, thereby limiting the effectiveness of surgical revascularization.

Cognitive disorders and postoperative delirium, observed in 15-30% of patients after CEA, adversely affect rehabilitation and long-term prognosis. To date, there are no reliable pharmacological strategies to prevent these complications.

In this context, inert gases have attracted significant interest as potential neuroprotective agents. Xenon, despite its proven efficacy, is limited by high cost and challenges in industrial production. Argon, in contrast, is accessible, safe, and technologically straightforward to administer. In preclinical models of stroke and ischemia-reperfusion, argon has demonstrated pronounced anti-apoptotic, anti-inflammatory, and antioxidant effects, mediated through the regulation of TLR2/4-, ERK1/2-, Nrf2-, and NF-κB-dependent signaling pathways. Its ability to suppress microglial activation towards the M1 phenotype and inhibit the NLRP3 inflammasome has been noted, which reduces neuroinflammation and decreases the volume of secondary neuronal damage. Short-term argon inhalation in healthy volunteers has shown a favorable safety profile with no adverse effects on cerebral hemodynamics.

Thus, it is highly relevant to clinically test the hypothesis that perioperative inhalation of an argon-containing gas mixture can reduce the incidence of ischemic brain injuries and cognitive impairments in patients undergoing CEA.

02

Conditions studied

  • Carotid Artery Disease
  • Carotid Artery Stenoses

Keywords

  • Carotid artery disease
  • Carotid artery stenosis
  • Carotid artery surgery
  • Neurocognitive disorders
  • postoperative delirium
  • Stroke
  • Neuroinflammation
  • Argon
  • Organ protection
03

In context

Carotid Stenosis Reclassified

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

This study's planned enrollment of 100 is close to the median of 102 across 192 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Compared within Carotid Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carotid Artery Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 years
  • elective carotid artery surgery
  • general anesthesia
  • written

Exclusion criteria

Exclusion Criteria:

  • The presence of any mental disorder according to the International Classification of Diseases 10th Revision which is confirmed by a psychiatrist.
  • The presence of any neuromuscular disease according to the International Classification of Diseases 10th Revision
  • Heart failure equal 3 or 4 class according to the Functional Classification
  • Pregnant or breast-feeding women
  • Inability to undergo a preoperative assessment for any reason
  • Previously enrolled in this trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Аrgon-oxygen breathing mixture

    Perioperative inhalation of an argon-oxygen mixture (70% argon, 30% oxygen)

    Drug: Аrgon-oxygen breathing mixture

  • Sham comparator
    Nitrogen-oxygen breathing mixture

    Perioperative inhalation of an nitrogen-oxygen mixture (70% nitrogen, 30% oxygen)

    Drug: Nitrogen-oxygen breathing mixture

Interventions

  • DrugАrgon-oxygen breathing mixture

    Patients receive a course of inhalations with an argon-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day

  • DrugNitrogen-oxygen breathing mixture

    Patients receive a course of inhalations with an nitrogen-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium

    Number of patients with even one positive confusion assessment method for the intensive care unit or 3-minute confusion assessment method

    Time frame: 30 days

Secondary outcomes

  1. Incidence of emergence delirium

    Number of patients with positive the confusion assessment method for the intensive care unit as soon as they reach Aldrete score of 9 points

    Time frame: 30 days

  2. Incidence of postoperative agitation

    Richmond agitation-sedation scale more or equal +2 evaluated from the end of volatile anesthetic supply to the moment when a patient reaches Aldrete score of 9 points Richmond agitation-sedation scale: minimum value = -5 (Unarousable - no response to voice or physical stimulation) maximum value = +4 (Combative - overtly combative or violent; immediate danger to staff) Adequate patients have the results of Richmond agitation-sedation score equal 0 (Alert and calm; Spontaneously pays attention to caregiver)

    Time frame: 30 days

  3. Duration of postoperative delirium

    30 days - number of days in which patient had positive confusion assessment method for the intensive care unit or 3-minute confusion assessment method

    Time frame: until 1 month after surgery

  4. Incidence of cognitive dysfunction

    reduction of ≥1 standard deviation in the Montreal Cognitive Assessment (MoCA) total z-score compared to the preoperative assessment

    Time frame: 30 days

  5. Incidence of overt stroke

    Number of overt strokes

    Time frame: 30 days

  6. Incidence of covert stroke

    Number of covert strokes

    Time frame: 30 days

  7. Length of stay in the intensive care unit

    Number of days in intensive care unit

    Time frame: 30 days

  8. Length of hospitalization

    Number of days in hospital

    Time frame: 30 days

  9. Serum level of S100 beta protein

    Serum level of S100 beta protein

    Time frame: 2 days after surgery

  10. Serum level of neuron-specific enolase

    Serum level of neuron-specific enolase

    Time frame: 2 days after surgery

  11. Serum level of interleukin-6

    Serum level of interleukin-6

    Time frame: 2 days after surgery

07

Study locations

2 of 2 sites recruiting
  • GBWZ of Moscow city hospital n.a. S.P. Botkin
    Moscow, 125284, Russia
    Recruiting
    • Viktoriya Antonova, PhD · Contactvantonova@fnkcrr.ru · +79385003034
    • Viktoriya Antonova, PhD · Sub investigator
  • Demikhov Municipal Clinical Hospital 68
    Moscow, Russia
    Recruiting
    • Viktoriya Antonova, MD, PhD · Contactvantonova@fnkcrr.ru · +79385003034
    • Dmitriy Makarevich, MD, PhD · Principal investigator
    • Viktoriya Antonova, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Decision of the local ethics committee

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 30, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07200180
Lead sponsor
Negovsky Reanimatology Research Institute
Collaborators
GBWZ of Moscow city hospital n.a. S.P. Botkin
Responsible party
Oleg A. Grebenchikov (The head of the laboratory in the Negovsky Reanimatology Research Institute, Negovsky Reanimatology Research Institute) — Principal investigator
First posted
Sep 30, 2025
Start date
Sep 22, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Oleg Grebenchikov, MD, PhD
Contact
oleg.grebenchikov@yandex.ru
+79686494147
Oleg Grebenchikov, MD, PhD
principal investigator · Negovsky Reanimatology Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion